QQQ   390.02 (+0.31%)
AAPL   191.25 (+0.68%)
MSFT   374.98 (-1.04%)
META   324.98 (-0.66%)
GOOGL   131.72 (-0.61%)
AMZN   147.14 (+0.72%)
TSLA   238.84 (-0.52%)
NVDA   468.27 (+0.12%)
NIO   7.20 (-0.96%)
BABA   73.88 (-1.34%)
AMD   121.19 (+0.02%)
T   16.71 (+0.84%)
F   10.59 (+3.22%)
MU   75.87 (-0.33%)
CGC   0.62 (+11.07%)
GE   122.97 (+0.96%)
DIS   92.39 (-0.32%)
AMC   6.97 (+4.81%)
PFE   28.67 (-5.91%)
PYPL   59.50 (+3.28%)
XOM   103.04 (+0.29%)
QQQ   390.02 (+0.31%)
AAPL   191.25 (+0.68%)
MSFT   374.98 (-1.04%)
META   324.98 (-0.66%)
GOOGL   131.72 (-0.61%)
AMZN   147.14 (+0.72%)
TSLA   238.84 (-0.52%)
NVDA   468.27 (+0.12%)
NIO   7.20 (-0.96%)
BABA   73.88 (-1.34%)
AMD   121.19 (+0.02%)
T   16.71 (+0.84%)
F   10.59 (+3.22%)
MU   75.87 (-0.33%)
CGC   0.62 (+11.07%)
GE   122.97 (+0.96%)
DIS   92.39 (-0.32%)
AMC   6.97 (+4.81%)
PFE   28.67 (-5.91%)
PYPL   59.50 (+3.28%)
XOM   103.04 (+0.29%)
QQQ   390.02 (+0.31%)
AAPL   191.25 (+0.68%)
MSFT   374.98 (-1.04%)
META   324.98 (-0.66%)
GOOGL   131.72 (-0.61%)
AMZN   147.14 (+0.72%)
TSLA   238.84 (-0.52%)
NVDA   468.27 (+0.12%)
NIO   7.20 (-0.96%)
BABA   73.88 (-1.34%)
AMD   121.19 (+0.02%)
T   16.71 (+0.84%)
F   10.59 (+3.22%)
MU   75.87 (-0.33%)
CGC   0.62 (+11.07%)
GE   122.97 (+0.96%)
DIS   92.39 (-0.32%)
AMC   6.97 (+4.81%)
PFE   28.67 (-5.91%)
PYPL   59.50 (+3.28%)
XOM   103.04 (+0.29%)
QQQ   390.02 (+0.31%)
AAPL   191.25 (+0.68%)
MSFT   374.98 (-1.04%)
META   324.98 (-0.66%)
GOOGL   131.72 (-0.61%)
AMZN   147.14 (+0.72%)
TSLA   238.84 (-0.52%)
NVDA   468.27 (+0.12%)
NIO   7.20 (-0.96%)
BABA   73.88 (-1.34%)
AMD   121.19 (+0.02%)
T   16.71 (+0.84%)
F   10.59 (+3.22%)
MU   75.87 (-0.33%)
CGC   0.62 (+11.07%)
GE   122.97 (+0.96%)
DIS   92.39 (-0.32%)
AMC   6.97 (+4.81%)
PFE   28.67 (-5.91%)
PYPL   59.50 (+3.28%)
XOM   103.04 (+0.29%)

AstraZeneca Stock Price, News & Analysis (NASDAQ:AZN)

$64.68
+0.09 (+0.14%)
(As of 03:04 PM ET)
Compare
Today's Range
$64.37
$65.06
50-Day Range
$61.89
$69.28
52-Week Range
$61.73
$76.56
Volume
2.80 million shs
Average Volume
5.05 million shs
Market Capitalization
$200.50 billion
P/E Ratio
34.04
Dividend Yield
1.41%
Price Target
$80.00

AstraZeneca MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
23.4% Upside
$80.00 Price Target
Short Interest
Healthy
0.26% of Shares Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
1.23mentions of AstraZeneca in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.11%
From $3.64 to $4.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

80th out of 949 stocks

Pharmaceutical Preparations Industry

27th out of 446 stocks


AZN stock logo

About AstraZeneca Stock (NASDAQ:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases, as well as a collaboration with BioCity Biopharma to evaluate a monoclonal antibody for the treatment of advanced hepatocellular carcinoma and a collaboration agreement with Cellectis. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock Price History

AZN Stock News Headlines

3 stocks that crushed earnings estimates and still tanked
Every earnings season, regardless of sector or industry, has its share of stocks that go down even after beating earnings expectations such as these stocks
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
AstraZeneca Pays Hefty Price For Chinese Weight-Loss Drug
AstraZeneca Launches Evinova Healthtech Business
AstraZeneca: Truqap Plus Faslodex Approved In US For HR+ Breast Cancer
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 9/11 Dividend
8/10/2023
Dividend Payable
9/11/2023
Last Earnings
11/08/2023
Today
12/01/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/08/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AZN
Employees
83,500
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$80.00
High Stock Price Target
$80.00
Low Stock Price Target
$80.00
Potential Upside/Downside
+23.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$3.29 billion
Pretax Margin
15.07%

Debt

Sales & Book Value

Annual Sales
$44.35 billion
Cash Flow
$5.13 per share
Book Value
$12.01 per share

Miscellaneous

Outstanding Shares
3,099,830,000
Free Float
N/A
Market Cap
$200.22 billion
Optionable
Optionable
Beta
0.51

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report














AZN Stock Analysis - Frequently Asked Questions

Should I buy or sell AstraZeneca stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AZN shares.
View AZN analyst ratings
or view top-rated stocks.

What is AstraZeneca's stock price target for 2024?

7 equities research analysts have issued 1 year target prices for AstraZeneca's stock. Their AZN share price targets range from $80.00 to $80.00. On average, they predict the company's stock price to reach $80.00 in the next twelve months. This suggests a possible upside of 23.4% from the stock's current price.
View analysts price targets for AZN
or view top-rated stocks among Wall Street analysts.

How have AZN shares performed in 2023?

AstraZeneca's stock was trading at $67.80 at the beginning of the year. Since then, AZN stock has decreased by 4.4% and is now trading at $64.83.
View the best growth stocks for 2023 here
.

Are investors shorting AstraZeneca?

AstraZeneca saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 8,100,000 shares, a drop of 10.1% from the October 31st total of 9,010,000 shares. Based on an average daily trading volume, of 5,180,000 shares, the short-interest ratio is currently 1.6 days.
View AstraZeneca's Short Interest
.

When is AstraZeneca's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our AZN earnings forecast
.

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) issued its earnings results on Wednesday, November, 8th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.84 by $0.03. The firm had revenue of $11.49 billion for the quarter, compared to analyst estimates of $11.55 billion. AstraZeneca had a net margin of 13.10% and a trailing twelve-month return on equity of 30.30%. The company's quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the company earned $0.84 EPS.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a semi-annual dividend on Friday, July 28th. Investors of record on Friday, August 11th will be given a dividend of $0.465 per share on Monday, September 11th. This represents a yield of 2%. The ex-dividend date of this dividend is Thursday, August 10th.
Read our dividend analysis for AZN
.

Is AstraZeneca a good dividend stock?

AstraZeneca (NASDAQ:AZN) pays an annual dividend of $0.91 per share and currently has a dividend yield of 1.42%. The dividend payout ratio is 47.89%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AZN will have a dividend payout ratio of 21.72% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AZN.

When did AstraZeneca's stock split?

AstraZeneca shares split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were distributed to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Pascal Soriot's approval rating as AstraZeneca's CEO?

2,350 employees have rated AstraZeneca Chief Executive Officer Pascal Soriot on Glassdoor.com. Pascal Soriot has an approval rating of 98% among the company's employees. This puts Pascal Soriot in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. 87.0% of employees surveyed would recommend working at AstraZeneca to a friend.

What other stocks do shareholders of AstraZeneca own?
Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (1.60%), Primecap Management Co. CA (1.42%), Jennison Associates LLC (0.74%), FMR LLC (0.68%), Morgan Stanley (0.43%) and Sanders Capital LLC (0.34%).
View institutional ownership trends
.

How do I buy shares of AstraZeneca?

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does AstraZeneca have any subsidiaries?
The following companies are subsidiares of AstraZeneca: AAPM Sar, AZ Reinsurance Limited, AZ-Mont Insurance Company, AZENCO2 Limited, AZENCO4 Limited, Acerta Pharma B.V., Acerta Pharma LLC, AcertaPharma, Aktiebolaget Hassle, Alexion Pharmaceuticals, Almirall, AlphaCore Pharma, Amylin Ohio LLC, Amylin Pharmaceuticals LLC, Archigen Biotech Limited, Ardea Biosciences, Ardea Biosciences Limited, Arrow Therapeutics, Arrow Therapeutics Limited, Aspire Therapeutics B.V., Astra Alpha Produtos Farmaceuticos Lda, Astra Export & Trading Aktiebolag, Astra Lakemedel Aktiebolag, Astra Pharmaceuticals Limited, Astra Tech International Aktiebolag, AstraPharm, AstraZeneca (Israel) Ltd, AstraZeneca (Thailand) Limited, AstraZeneca (Wuxi) Trading Co. Ltd, AstraZeneca A/S, AstraZeneca AB, AstraZeneca AG, AstraZeneca AS, AstraZeneca Asia-Pacific Business Services Sdn Bhd, AstraZeneca B.V., AstraZeneca BioVentureHub AB, AstraZeneca Biotech AB, AstraZeneca Bulgaria EOOD, AstraZeneca CAMCAR Costa Rica S.A., AstraZeneca CAMCAR S.A., AstraZeneca Canada Inc., AstraZeneca China UK Limited, AstraZeneca Collaboration Ventures LLC, AstraZeneca Colombia S.A.S., AstraZeneca Continent B.V., AstraZeneca Czech Republic s.r.o., AstraZeneca Death In Service, AstraZeneca Dunkerque Production SCS, AstraZeneca Eesti OÜ, AstraZeneca Egypt for Pharmaceutical Industries JSC, AstraZeneca Egypt for Trading LLC, AstraZeneca Employee Share Trust Limited, AstraZeneca FZ-LLC, AstraZeneca Farmaceutica Chile Limitada, AstraZeneca Farmaceutica Holding Spain S.A., AstraZeneca Farmaceutica Spain S.A., AstraZeneca Finance Limited, AstraZeneca Finance S.A.S., AstraZeneca Gamma B.V., AstraZeneca GmbH, AstraZeneca Health Care Division S.A. de C.V., AstraZeneca Holding Aktiebolag, AstraZeneca Holding France S.A.S., AstraZeneca Holding GmbH, AstraZeneca Holdings B.V., AstraZeneca Holdings Pty Limited, AstraZeneca Hong Kong Limited, AstraZeneca Ilac Sanayi ve Ticaret Limited Sirketi, AstraZeneca India Private Limited, AstraZeneca Industries LLC, AstraZeneca Intermediate Holdings Limited, AstraZeneca International Holdings Aktiebolag, AstraZeneca Investment (China) Co. Ltd, AstraZeneca Investments Limited, AstraZeneca Japan Limited, AstraZeneca Jota B.V., AstraZeneca K.K., AstraZeneca Kft, AstraZeneca Korea Co. Ltd, AstraZeneca Latvija SIA, AstraZeneca Lietuva UAB, AstraZeneca Limited, AstraZeneca Luxembourg S.A., AstraZeneca Maroc SARLAU, AstraZeneca Nigeria Limited, AstraZeneca Nominees Limited, AstraZeneca Nordic AB, AstraZeneca OY., AstraZeneca PTY Limited, AstraZeneca Pars Company, AstraZeneca Peru S.A., AstraZeneca Pharma India Limited, AstraZeneca Pharma Poland Sp.z.o.o., AstraZeneca Pharma S.R.L., AstraZeneca Pharmaceutical (China) Co. Ltd, AstraZeneca Pharmaceuticals (Ireland) Designated Activity Company, AstraZeneca Pharmaceuticals (Phils.) Inc., AstraZeneca Pharmaceuticals (Pty) Limited, AstraZeneca Pharmaceuticals Aktiebolag, AstraZeneca Pharmaceuticals Co. Limited, AstraZeneca Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP, AstraZeneca Pharmaceuticals Limited, AstraZeneca Pharmaceuticals Pakistan (Private) Limited, AstraZeneca Pharmaceuticals Technologies (Beijing) Co. Ltd, AstraZeneca Produtos Farmaceuticos Lda, AstraZeneca Quest Limited, AstraZeneca Rho B.V., AstraZeneca S.A., AstraZeneca S.A. / N.V., AstraZeneca S.A. de C.V., AstraZeneca S.A.S., AstraZeneca Sdn Bhd, AstraZeneca Share Trust Limited, AstraZeneca Sigma B.V., AstraZeneca Singapore Pte Limited, AstraZeneca SpA, AstraZeneca Sweden Investments Limited, AstraZeneca Södertälje 2 AB, AstraZeneca Taiwan Limited, AstraZeneca Treasury B.V., AstraZeneca Treasury Limited, AstraZeneca Tunisie SaRL, AstraZeneca UK Limited, AstraZeneca US Investments Limited, AstraZeneca Ukraina LLC, AstraZeneca Venezuela S.A., AstraZeneca Vietnam Company Limited, AstraZeneca Zeta B.V, AstraZeneca d.o.o, AstraZeneca do Brasil Limitada, AstraZeneca Österreich GmbH, Atkemix Nine Inc., Atkemix Ten Inc., BMS Holdco Inc., Cambridge Antibody Technology, Cambridge Antibody Technology Group Limited, Centus Biotherapeutics Limited, Corpus Christi Holdings Inc., Definiens GmbH, Definiens Inc., Drimex LLC, Gotland Pharma S.A., Guangdong BeiKang Pharmaceutical Company Ltd, IPR Pharmaceuticals Inc., KuDOS Horsham Limited, KuDOS Pharmaceuticals Limited, KuDOS Pharmaceuticals Ltd, Laboratorio Beta S.A., Laboratorio Lailan S.A., Laboratorio Odin S.A., Laboratorio Tau S.A., MedImmune LLC, MedImmune Limited, MedImmune Pharma B.V, MedImmune U.K. Limited, MedImmune Ventures Inc, Montrose Chemical Corporation of California, Novastra Promoção e Comércio Farmacêutico Lda, Novastuart Produtos Farmaceuticos Lda, Novexel, Omthera Pharmaceuticals, Omthera Pharmaceuticals Inc., Optein Inc., P.T. AstraZeneca Indonesia, Pearl Therapeutics, Pearl Therapeutics Inc, Pharmaceutical Manufacturing Company Pty Limited, Pharmaceutical Manufacturing Division Pty Limited, SPA AstraZeneca Al Djazair, Simesa SpA, Sofotec GmbH, Spirogen Sarl, Stauffer Management Company LLC, Stuart Pharma Aktiebolag, Stuart-Produtos Farmacêuticos Lda, Symbicom Aktiebolag, Takeda Respiratory Business, Tika Lakemedel Aktiebolag, Trustee Limited, Unipessoal Lda, WuXi MedImmune Biopharmaceutical Co, ZS Pharma, ZS Pharma Inc, Zenco (No. 8) Limited, Zeneca Epsilon – Produtos Farmacêuticos Lda, Zeneca Finance (Netherlands) Company, Zeneca Holdings Inc., Zeneca Ilac Sanayi Ve Ticaret Anonim Sirketi, Zeneca Inc., Zeneca Wilmington Inc., and Zenecapharma Produtos Farmaceuticos .
Read More
This page (NASDAQ:AZN) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -